Search
Take Action
Pfizer and Axitinib (AG-013736)
Pfizer is Announcing a New Phase 3 Trial for Axitinib (AG-013736)
Pfizer will soon announce the opening of a large scale, Phase 3 randomized trial in the U.S. and 20 other countries testing axitinib versus sorafenib (Nexavar) in patients who have previously failed a therapy, either cytokine (Interleukin-2 or Interferon) or a targeted therapy including Sutent. Pfizer expects to start the trial this summer and hopes to get the first IRB approval in June or July, 2008.
Dear Senator, Approve Our Dear Colleague Letter !
We still need your help! The Senate is scheduled to vote on our $15 million request in July!
The Dear Colleague letter requesting the $15 million appropriation, which, if granted, would increase the federal research budget for kidney cancer research by half is scheduled to be voted on in July.
Please call, and have all your friends and family call your/their Defense Appropriations Subcommittee Senators' health aides and ask them to have their Senators approve the Dear Colleague letter that is asking for the $15 million appropriation.
The Senators on the Defense Appropriations Subcommittee are:
Democratic Subcommittee Members:Senator Daniel Inouye (Chairman) (HI)
Senator Robert C. Byrd (WV)
Senator Patrick Leahy (VT)
Senator Tom Harkin (IA)
Senator Byron Dorgan (ND)
Senator Richard Durbin (IL)
Look Up Your Congressman
Step 1: Get your 9-digit zip code (zip+4) from the following website:
http://zip4.usps.com/zip4/welcome.jsp (United States Postal Service)
Step 2: Enter your 9-digit zip code into the following website:
http://www.house.gov (US House of Representatives)
Look Up Your Senator
Go to the following website:
http://www.senate.gov and click on Senators
Congressional Committees
ACKC is currently seeking Congressional approval for appropriating $15 million to the Congressionally Directed Medical Research Programs (CDMRPs) managed by the Department of Defense. Two Dear Colleague letters were written and signed by members of Congress requesting the appropriation of the $15 million. One letter went to the Chairman and Ranking Member of the Senate Defense Appropriations Subcommittee and the other letter went to the Chairman and Ranking Member of the House Military Quality of Life and Veterans Affairs and Related Agencies Appropriation Subcommittee.
If you are a constituent of any of these Senators or Representatives and they have not signed on to the Dear Colleague letter, please make your voice heard. Contact ACKC for any assistance you need to contact your elected representatives.
Award to Researcher Will Advance Valuable Screening
Test would be first to detect deadly kidney cancer
Paul CairnsOn March 2, 2006, Action to Cure Kidney Cancer (ACKC) awarded a $45,000 grant to Paul Cairns, Ph.D., of Fox Chase Cancer Center in Philadelphia to purchase an important piece of equipment to help his laboratory develop a urine test that will detect all types of kidney cancer (renal cell carcinoma) in the earliest stages of disease. The new equipment will speed up the project and result in a more accurate test--which would be the first to be used against this silent killer.
Dr. Cairns' work is part of the Early Detection Research Network, a program set up by the National Cancer Institute that issues grants designed to accelerate collaboration and speed up the translation of early detection projects to clinical settings.
